Posted by Michael Wonder on 19 Oct 2020
Inventiva receives FDA fast track designation in MPS VI for its clinical-stage asset odiparcil
19 October 2020 - Inventiva today announced that the U.S. FDA has granted fast track designation to odiparcil, the Company’s clinical-stage drug candidate for the treatment of MPS type VI, a rare and progressive genetic disorder.
